Pharming Group N.V. reports 1H results
- BySeeking Alpha-
Here's a roundup of top developments in ...Full story available on Benzinga.com
Gene therapy developer Orchard Therapeutics (ORTX) is collaborating with commercial-stage biopharmaceutical company Pharming Group (PHAR) to develop and bring to market OTL-105, a...
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.